Novocure's Pancreatic Device Ends Quarter With 276 Patients And $3.7 Million In Sales As Rival Drug Crowds Clinics
CEO Frank Leonard says practices swamped by a rival's launch limit access for Optune Pax, and Novocure plans two small KRAS-inhibitor trials.
Novocure's Optune Pax, its newly launched pancreatic cancer device, finished the third quarter with 276 active patients and $3.7 million in net revenue, CEO Frank Leonard said on the company's Thursday earnings call, as momentum slowed in the U.S. after a rival drug arrived. Novocure makes wearable devices that deliver electric fields meant to kill cancer cells.
A rival launch crowds the clinics
Leonard said the company's ability to reach practices to detail Optune Pax is "significantly limited at this time," and he acknowledged "the challenges in the OptumPax launch." He tied the slowdown to the introduction of daraxonrasib, a rival drug approved for a different pancreatic indication than the device.
Leonard described the problem as one of share of voice. A flood of patients asking for the drug, he said, triggers insurance appeals in practices and, as treatment proceeds, a lot of skin irritation, leaving staff "overwhelmed."
Asked by a Piper Sandler analyst whether patients were switching, Leonard said Novocure is not seeing patients leave Optune Pax in substantial numbers for the rival. Nor does the data show strong signs of widespread first-line use of the drug, he said, except in patients who cannot tolerate standard chemotherapy. That points him to the hypothesis that practices are "just being simply overwhelmed."
He also pointed to ESMO, the cancer conference in Madrid, where Optune Pax drew the most unsolicited inquiries at the company's booth.
Two small trials with KRAS inhibitors
Novocure plans two safety and feasibility studies pairing Optune Pax with KRAS inhibitors, drugs that target a cancer-driving gene mutation. One, in locally advanced disease, will use Verastem's inhibitor with chemotherapy; the other, in metastatic disease, will use the rival drug. Leonard said both are expected to start in the first half of 2027.
The Verastem study is expected to enroll around 25 patients, with the rival-drug study enrolling a similar number.
On payers, Leonard said the next U.S. milestone is inclusion in the NCCN pancreatic cancer guidelines, typically published once a year, at year-end or early in the new year. Novocure has one coverage policy so far, from Elevance.
Strong quarter around the weak launch
CFO Christoph Brackmann reported net revenue of $193 million, up 16% from a year earlier, and raised 2026 revenue guidance to between $736 million and $743 million. Net loss narrowed to $10 million from $37 million. Gross margin was 77%, against 73% a year ago.
Optune Gio, the company's glioblastoma device, ended the quarter with 4,729 patients on therapy, up 11%. Optune Lua, for lung cancer, had 255 active patients and $8 million in revenue, with Japan contributing 110 patients and $4 million.
Leonard said Japanese reimbursement for Optune Pax is expected in the first quarter of 2027, and that the company expects Optune Pax to return to growth in coming quarters.
The NCCN guideline update, which Leonard said could come at year-end or early in the new year, is the next payer milestone for Optune Pax.
Sources
- NovoCure beats top-line and bottom-line estimates; updates FY26 outlook | Seeking Alpha — seekingalpha.com
- NovoCure: Q3 Earnings Snapshot | 9news.com — Associated Press
- NovoCure: Q3 Earnings Snapshot – WTOP News — wtop.com
- NovoCure: Q3 Earnings Snapshot — seattlepi.com
- NovoCure: Q3 Earnings Snapshot | wusa9.com — Associated Press
More on Novocure
- Novocure's Raised Outlook Implies A Fourth-Quarter Revenue Dip, And The CFO Walks Through Why
- Novocure Raises 2026 Revenue Outlook To $736 Million-$743 Million After Record Quarter
- Novocure Turns Cash-Flow Positive For Nine Months, With $22.8 Million From Unpaid Bills And A $25 Million Debt Slice Now Due